Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Neoplasms

abstract

  • This retrospective analysis of five placebo-controlled clinical trials does not support a decreased time to disease progression, increased mortality, or altered disease progression pattern after cessation of bevacizumab therapy.

publication date

  • January 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.30.2794

PubMed ID

  • 21098326

Additional Document Info

start page

  • 83

end page

  • 8

volume

  • 29

number

  • 1